- Home
- ARAY vs ACIU Comparison
ARAY vs ACIU Comparison
Compare ARAY & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARAY
- ACIU
- Stock Information
- Founded
- ARAY 1990
- ACIU 2003
- Country
- ARAY United States
- ACIU Switzerland
- Employees
- ARAY N/A
- ACIU N/A
- Industry
- ARAY Medical/Dental Instruments
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- ARAY Health Care
- ACIU Health Care
- Exchange
- ARAY Nasdaq
- ACIU Nasdaq
- Market Cap
- ARAY 229.3M
- ACIU 247.4M
- IPO Year
- ARAY 2007
- ACIU 2016
- Fundamental
- Price
- ARAY $1.78
- ACIU $1.80
- Analyst Decision
- ARAY
- ACIU Strong Buy
- Analyst Count
- ARAY 0
- ACIU 2
- Target Price
- ARAY N/A
- ACIU $12.00
- AVG Volume (30 Days)
- ARAY 382.4K
- ACIU 190.8K
- Earning Date
- ARAY 04-30-2025
- ACIU 03-13-2025
- Dividend Yield
- ARAY N/A
- ACIU N/A
- EPS Growth
- ARAY N/A
- ACIU N/A
- EPS
- ARAY N/A
- ACIU N/A
- Revenue
- ARAY $453,140,000.00
- ACIU $30,136,397.00
- Revenue This Year
- ARAY $6.97
- ACIU $120.91
- Revenue Next Year
- ARAY $5.02
- ACIU $13.82
- P/E Ratio
- ARAY N/A
- ACIU N/A
- Revenue Growth
- ARAY 1.26
- ACIU 84.51
- 52 Week Low
- ARAY $1.40
- ACIU $1.77
- 52 Week High
- ARAY $2.95
- ACIU $4.98
- Technical
- Relative Strength Index (RSI)
- ARAY 38.43
- ACIU 20.92
- Support Level
- ARAY $1.75
- ACIU $1.95
- Resistance Level
- ARAY $1.89
- ACIU $2.05
- Average True Range (ATR)
- ARAY 0.07
- ACIU 0.12
- MACD
- ARAY 0.01
- ACIU -0.03
- Stochastic Oscillator
- ARAY 25.00
- ACIU 4.10
About ARAY Accuray Incorporated
Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise, innovative treatment solutions which set the standard of radiation therapy care with the aim of helping patients live better lives. The company's technology, The CyberKnife, is used to treat multiple types of cancer and tumors throughout the body. The CyberKnife Systems automatically track, detect and correct for a tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation with sub-millimetre accuracy while patients breathe normally, without manual user intervention.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.